Researchers at MIT have unveiled a way to temporarily reboot aging immune systems, using a targeted mRNA therapy that turns the liver into a short‑lived factory for powerful T‑cell survival signals.
VANCOUVER, Washington, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal ...